A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer · 16.12.2020 · 2020 · 1-7
DOI: 10.1155/2020/4242989 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prostate Cancer, erschienen am 16.12.2020. Verfasst von Aseem Samar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Bhagwan Mahaveer Cancer Hospital and Research Centre, Jaipur, Rajasthan 302017, India. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To evaluate the efficacy and safety of nanosomal docetaxel lipid suspension (NDLS, DoceAqualip) in patients with metastatic castration-resistant prostate cancer (mCRPC). Materials and Methods. In this multicenter, retrospective study, we analyzed the medical charts of mCRPC patients, who were treated with NDLS administered as 2-weekly (50 mg/m2) or 3-weekly regimens (75 mg/m2). The study endpoints were prostate-specific antigen (PSA) response (>50% PSA decline from baseline), PSA progression (PSA increase from baseline beyond 12 weeks: ≥25% and ≥2 ng/mL), median PSA decline, and time-to-treatment failure (TTF). Overall survival (OS) and safety were also evaluated.
Results
Data of 24 patients with mCRPC were analyzed in this study. NDLS was administered as a 2-weekly regimen in 37.5% (9/24; all first-line) patients and as a 3-weekly regimen in 62.5% patients (15/24; first-line: 20% (3/15), second-line: 80% (12/15)). Overall, PSA response was reported in 66.7% (16/24) patients. The PSA response was 77.8% (7/9 patients) in the 2-weekly group and 60% (9/15 patients) in the 3-weekly group. The median decline in PSA was 96.31% in the 2-weekly group and 83.29% in the 3-weekly group; the median TTF was 6.7 and 6.5 months in the 2 weekly group and 3-weekly group, respectively. The median OS was 14.6 months (follow-up: 5.5–25.8 months) in the 2-weekly group whereas it was not reached in the 3-weekly group (follow-up: 7.9–15.6 months). The most common hematological AEs were anemia, lymphopenia, thrombocytopenia, and neutropenia whereas nausea, weakness, constipation, vomiting, and diarrhea were the most common (≥10%) nonhematological AEs. Overall, NDLS treatment was well tolerated without any new safety concerns.
Conclusions
Nanosomal docetaxel lipid suspension (2-weekly or 3-weekly) was effective and well tolerated in patients with metastatic castration-resistant prostate cancer.
Autor:innen und Institutionen
- Bhagwan Mahaveer Cancer Hospital and Research Centre, Jaipur, Rajasthan 302017, India.
- Jawaharlal Nehru Cancer Hospital & Research Centre, Bhopal, Madhya Pradesh 462001, India.
- VS Hospital, Madras Cancer Institute, Advanced Cancer Care, Chennai, Tamil Nadu 600031, India.
- Medical Affairs and Clinical Development, Intas Pharmaceuticals Ltd. Sola, Ahmedabad, Gujarat 380054, India.
- Jina Pharmaceuticals Inc., Libertyville, Illinois 60048, USA.
ORCID-Profile: Imran Ahmad
Zitieren
APA
Samar, A., Tiwari, S., Subramanian, S., Joshi, N., Sejpal, J., Khan, M. A., & Ahmad, I. (2020). A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer. Prostate Cancer, 2020, 1-7. https://doi.org/10.1155/2020/4242989
Vancouver
Samar A, Tiwari S, Subramanian S, Joshi N, Sejpal J, Khan MA, et al. A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer. Prostate Cancer. 2020;2020:1-7. doi:10.1155/2020/4242989
BibTeX
@article{Samar2020,
author = {Samar, Aseem and Tiwari, Srikant and Subramanian, Sundaram and Joshi, Nisarg and Sejpal, Jaykumar and Khan, Mujtaba A and Ahmad, Imran},
title = {A Multicentric, Retrospective Efficacy and Safety Study of Nanosomal Docetaxel Lipid Suspension in Metastatic Castration-Resistant Prostate Cancer},
journal = {Prostate Cancer},
year = {2020},
volume = {2020},
pages = {1--7},
doi = {10.1155/2020/4242989}
}
EUVIMED